Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Grants Orphan Drug Designation for Sakigake Product Sirolimus, Others
December 21, 2015
- Govt to Shed 28 Bil. Yen via Huge Seller Drugs, 20 Bil. Yen via Existing Re-Pricing Rule; Physicians to Win “Plus” Revision
December 21, 2015
- Shipments of Kaketsuken’s Hep B Vaccine Likely to Resume Early Next Year
December 18, 2015
- MHLW to Carefully Discuss Cost Effectiveness of Prevenar 13 for Its Elderly Use under National Program
December 18, 2015
- ICH Reaches Agreement to Treat Subjects with Similar Ethnic Factors as Single Populations Regardless of Nationality
December 18, 2015
- PMDA Beating Targets for Overall Review Time in FY2015
December 18, 2015
- Chuikyo Approves Plan to Introduce Cost-Effective Assessments on Trial Basis; Selection of Products to Begin Next April
December 17, 2015
- Premium for Sakigake Products Clears Chuikyo Subcommittee
December 17, 2015
- Survey Finds Unexpectedly Low Market Prices for Injectable Generics; Industry to Accept 50% Rule
December 17, 2015
- Chuikyo Subcommittee OKs Outline of FY2016 Drug Pricing Reform, Rollout of “Huge Seller” Re-Pricing
December 17, 2015
- PMDA Plans to Increase Inspection Staff in Response to Kaketsuken Scandal
December 17, 2015
- Japan to Draw Up Action Plan on Drug Resistance: Health Minister
December 16, 2015
- MHLW to Establish Task Force in Response to Scandal at Kaketsuken
December 16, 2015
- Diet Submission of Clinical Research Bill Expected for Next Year: Panel Member
December 15, 2015
- More than 10 Regenerative Medicine Products Seeking Sakigake Designation: MHLW Official
December 15, 2015
- Chuikyo Discusses Optimizing Health Coverage for Poultices, Vitamins
December 14, 2015
- PMDA Reviewing Use of Ofev in Patients with Liver Dysfunction
December 14, 2015
- LDP OKs Taxation Changes for FY2016; R&D Tax Credit to Remain Intact
December 11, 2015
- 6 Drug Makers to Participate in AMED’s Drug Discovery Consortium
December 11, 2015
- First Generics for Jzoloft, Other Brands to Join NHI Price List on Dec. 11
December 10, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…